Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer

Bristol Myers Squibb snagged an FDA go-ahead to open another front in Opdivo's rivalry with Merck & Co.'s Keytruda.

The FDA approved the combination of Opdivo and Exelixis’ tyrosine kinase inhibitor Cabometyx for previously untreated advanced renal cell carcinoma—the exact same indication Merck and Pfizer’s PD-1/TKI pairing, Keytruda and Inlyta, won back in April 2019.